S.M. Collin

Articles by S.M. Collin

61 Economic Burden of Neutropenia Among Patients Treated for HR+/HER2– and Triple-Negative Metastatic Breast Cancer in the United States: A Retrospective Claims Analysis

ByMarvin Nguyen,Ruchit Shah,S.M. Collin,Y. Shi

June 17th 2026

This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.

Latest Updated Articles

S.M. Collin

Articles by S.M. Collin

61 Economic Burden of Neutropenia Among Patients Treated for HR+/HER2– and Triple-Negative Metastatic Breast Cancer in the United States: A Retrospective Claims Analysis

Latest Updated Articles

Trending on CancerNetwork

Analyzing ADC Options Across Metastatic TNBC

Arlo-Cel Produces Deep Responses in Pretreated R/R Multiple Myeloma

64 A Phase I/II Study of Pembrolizumab and Anti-CD3 x Anti-HER2 Armed Activated T-Cells in Metastatic Breast Cancer

Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma

CD47 Antibody Combo Shows Meaningful Activity in Previously Untreated AML